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Reactive carbonyl species (RCS)mainly reacts with lysine and arginine residues of proteins to form advanced glycation end products
(AGEs). Histone was glycoxidated with glyoxal and methylglyoxal. It was characterized by polyacrylamide gel electrophoresis
and quenching studies involving penicillamine and aminoguanidine as carbonyl scavengers. Further characterization of histone
modified with methylglyoxal was done by UV, fluorescence, and IR spectrophotometry. Spectral analysis of the protein clearly
demonstrates structural perturbation in the histone by methylglyoxal. Methylglyoxal-induces cross-linking in the protein leading
to aggregation. Role of methylglyoxal mediated glycoxidation of histone in type 1 diabetes was also undertaken. Antibodies were
detected against glycoxidated histone in sera of type 1 diabetes patients by solid-phase enzyme immunoassay.The findings indicate
that as a result of structural perturbation in histone bymethylglyoxal, themodified histonemay be involved in production of serum
antibodies in the diabetes patients.
1. Introduction
There is overwhelming evidence for involvement of reactive
oxygen species (ROS) in a number of pathophysiological
conditions such as diabetes, cancer, and aging but the studies
linking reactive carbonyl species (RCS) to the conditions
are limited [1, 2]. RCS, such as methylglyoxal, is produced
by degradation of lipid peroxidation products, early protein
glycation adducts, and as a byproduct of glycolysis. RCS
modification of histone results in cross-linking of proteins
and induces ROS-dependent cleavage of plasmid DNA [3].
The proteasome degradation of RCS products is not complete
and remnants may accumulate and cause epigenetic changes
aswell as furtherDNAandprotein damage [4]. Earlier studies
have shown that histones from liver cells of diabetic rats
contain high level of AGEs [5]. We [6] have found anti-
genicity of glycated poly-L-lysine in experimental animals
and autoantibodies were also detected against the modified
lysine polypeptide in diabetes patients. A recent work has
demonstrated in vivo formation of RCS-mediated AGEs in
histoneH
1
using antibodies against oxidative protein adducts
[7]. This study characterizes methylglyoxal-modified histone
(a lysine-rich protein) and evaluates its role in type 1 diabetes
patients.
2. Materials and Methods
2.1. Chemicals. Calf thymus whole histones (type II-A) and
methylglyoxal were purchased from Sigma (St. Louis, MO,
USA). Polystyrene flat bottom UV microtiter plates were
obtained from Greiner BioOne (Germany). All other chem-
icals and reagents used in the study were of the highest
analytical grade.
2.2. Serum Samples. Serum samples of various type 1 diabetes
patients proven with diagnostic tests were obtained from
Sir Sunderlal Hospital, IMS, BHU, Varanasi, India. These
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samples were routine determinations and were not specif-
ically obtained for the study. Serum samples from normal
healthy subjects who gave prior informed consent were
used as control. The study has been approved by the ethics
committee.
All serum samples were decomplemented at 56∘C for 30
min before use.
2.3. Preparation of Methylglyoxal-Modified Histone. Histone
was glycoxidated as described earlier with minor modifica-
tions [3, 8]. Briefly, histone (1mg/mL) in phosphate-buffered
saline (PBS, pH 7.4) was modified by separate incubation
with glyoxal (1 and 2mM) and methylglyoxal (1 and 2mM)
in 0.25M sodium phosphate buffer, pH 7.4, at 37∘C for 24 h.
Unmodified histone dissolved in the same buffer served
as control. Low concentration of RCS is taken as it binds
preferentially to lysine and arginine-rich histones and rapidly
forms dimers and polymers [9].
2.4. Effect of Carbonyl Scavengers on Methylglyoxal-Modified
Histone. Effect of scavengers on RCS modification of his-
tones was determined by addition of coincubatedmixtures of
penicillamine/aminoguanidinewithmethylglyoxal or glyoxal
to histones and incubation of the reaction mixture at 37∘C
for 24 hr. At the end of incubation, fluorescence of the assay
mixture was read after excitation at 320 nm and percent
quenching was calculated.
2.5. Polyacrylamide Gel Electrophoresis. Methylglyoxal-
induced alteration in histone was examined by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) as described previously on 15% gel under reducing
conditions, followed by silver staining as described previously
[3].
2.6. UV Spectrophotometry. The UV absorption characteris-
tics of control and modified histone were recorded on UV-
visible spectrophotometer (Biotek, model FLx800) between
200 and 400 nm using UV microtiter plates. The increase
in absorbance (hyperchromicity) was calculated using the
following formula:
Hyperchromicity (%) = (
𝐴modified − 𝐴control
𝐴modified
) × 100.
(1)
2.7. Fluorescence Study. Control and modified histones were
subjected to fluorescence studies on spectrofluorophotome-
ter (Hitachi, model F-2500). Fluorescence was measured at
25 ± 0.1
∘C in cuvette of 1 cm pathlength, with slit width fixed
at 10 nm. Formation of AGE-chromophores on histone was
measured by AGE-type fluorescence at 320/380, 335/385 nm
(𝜆ex/𝜆em). Increase in fluorescence intensity (FI) was calcu-
lated using the following formula:
% Increase of FI = (
FImodified − FIcontrol
FImodified
) × 100. (2)
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Figure 1: SDS-PAGE (15%) of native histone (lane 1) and histone
modified with 1 and 2mMmethylglyoxal (lanes 2 and 3, resp.) and 1
and 2mM glyoxal (lanes 4 and 5, resp.). Electrophoresis was carried
out for 3 h at 80 volts and the gel was visualized using silver staining.
2.8. FTIR Spectroscopy. The FTIR absorption spectra of the
samples were recorded on Nicolet 5700 FTIR spectrometer
(Thermo Corporation) in the range from 1500 to 1700 cm−1
with a nominal resolution of 4 cm−1. All measurements
were carried out at room temperature. Automated spectra of
control and modified histones were obtained from the sub-
traction spectra [(control + buffer)− (buffer)] and [(control +
modified + buffer) − (control + buffer)].
2.9. Detection of Antibodies against Methylglyoxal-Modified
Histone in Type 1 Diabetes Patients. Presence of antibodies
against the modified histone in the sera of type 1 diabetes
patients was evaluated by solid-phase enzyme immunoas-
say. Enzyme-linked immunosorbent assay (ELISA) was per-
formed on polystyrene plates as described previously [10].
Absorbance (𝐴) was monitored at 410 nm on an automatic
microplate reader and mean of duplicate readings for each
sample was recorded. Results have been expressed as a mean
of 𝐴 test − 𝐴control.
3. Results & Discussion
RCS-induced alteration in histone was examined by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) on 15% polyacrylamide gel after silver staining. The
migration pattern of silver-stained bands during SDS-PAGE
is shown in Figure 1. The pattern of native histone revealed
sharp bands of linker and core fractions (lane 1) which
underwent significant changes upon modification with 1 and
2mM methylglyoxal (lanes 2 and 3, resp.) and 1 and 2mM
glyoxal (lanes 4 and 5, resp.). Both of the modified his-
tones exhibited slightly higher-molecular-weight core histone
fractions (lanes 3 and 5), having reduced mobility in the
gel compared to the native ones. The modifier produced
aggregation of histone molecules into high molecular weight
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Figure 2: Fluorescence inhibition by penicillamine (P) and
aminoguanidine (AG) during incubation of histones with methyl-
glyoxal (MG) and glyoxal (Gly).
polymers, bands of which were restricted to top of the stack-
ing gel. A more extensive histone polymerization caused by
methylglyoxal, with a 2mM concentration, showed that it
was a slightly more effective protein cross-linker. Glycation-
mediated cross-linking of proteins is known to produce
dimers and high-molecular-weight polymers having reduced
mobility in electrophoresis [11].
Penicillamine and aminoguanidine used in the present
study are potent carbonyl scavengers and exert a direct effect
on RCS. When the scavengers (3mM) were present in the
RCS-modified reaction mixture, the corresponding results
were shown in Figure 2. They showed significant inhibitory
effect on the fluorescence induced by both methylglyoxal-
and glyoxal-modified histones. There was quenching of 58%
and 69% in fluorescence intensity of methylglyoxal- and
glyoxal-modified histones by penicillamine while it was 51%
and 65% by aminoguanidine. This study confirmed involve-
ment of the RCS in glycoxidation of histones and indicate that
methylglyoxal was a more effective modifier than glyoxal.
Histone modified with different concentrations of
methylglyoxal was further characterized by spectral
techniques. UV and fluorescence data of histone modified
withmethylglyoxal are summarized in Table 1. Native histone
had characteristic absorption peak at 206 nm due to its lysine
content (Figure 3). Upon modification with methylglyoxal,
increase in absorbance was recorded, extent of which was
dependent on the modifier concentration. Modified histone
samples also exhibited new broad peak at 320 nm. AGE
adducts of lysine and arginine residues in glycated proteins
are determined by AGE-specific absorbance at 330 nm [12].
The hyperchromicity exhibited by histone, modified with 1
and 2mM methylglyoxal, were 41% and 76%, respectively,
at 320 nm. The increase in absorbance and appearance of
AGE-specific peak in histone modified with the RCS is an
indication of structural changes in the histones.
AGE formation in methylglyoxal-modified histone led to
an increase in fluorescence intensity, associated with shift
in the emission maximum from 419 nm (native histone)
Table 1: UV and fluorescence data of native and methylglyoxal
modified histones under identical experimental conditions.
Native
histone
Methylglyoxal-
modified
histone
Modification
UV absorbance
at 320 nma 0.22 0.37 41.2%
UV absorbance
at 320 nmb 0.22 0.76 76.2%
Fluorescence
intensitya
(Ex. 320 nm)
222
(Em. 419 nm)
335
(Em. 413 nm) 33.7%
Fluorescence
intensityb
(Ex. 320 nm)
222
(Em. 419 nm)
1220
(Em. 440 nm) 81.7%
a and b represent 1 and 2mM concentrations, respectively, of the histone
modifier.
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Figure 3: Absorption spectra of native histone (—) and histone
modified with 1mM (⋅ ⋅ ⋅ ) and 2mM (- -) methylglyoxal.
to 413 and 440 nm in presence of 1 and 2mM methylgly-
oxal, respectively, upon excitation at 320 nm (Figure 4). The
observed increase in intensity was 34% at 413 nm (1mM
methylglyoxal) and 82% at 440 nm (2mM methylglyoxal).
However, the intensity enhancement was 26% at 419 nm and
74% at 438 nm with 1 and 2mM methylglyoxal (data not
shown), upon excitation at 335 nm. This observation may
be attributed to rise in the level of AGE adduct in histone
induced by increasing concentration of RCS. The emission
wavelength between 405–410 nm has been shown to reflect
AGE structures of argpyrimidine and pentosidine [12].
The conformational changes in RCS-modified histone
were determined by FTIR spectra (Figure 5). There was shift
in position and intensity of amide bandswith respect to native
histone at pH 7.4. Amide I gives rise to infrared bands in
the region between 1600 and 1700 cm−1 and is considered
a sensitive probe to study secondary structures of proteins,
namely, random coils,𝛼 helix, and𝛽 sheets.Themain spectral
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Figure 4: Fluorescence emission spectra of native histone (—) and
histone modified with 1mM (⋅ ⋅ ⋅ ) and 2mM (- -) methylglyoxal.
Excitation, 320 nm.
Wavenumber (cm−1)
1500 1600 1700
1641
1622
1580
15431519
1643 1674
1605
1524 1557
Figure 5: FTIR spectra of histone (—)modified with methylglyoxal
(⋅ ⋅ ⋅ ).
features of native histone were characterized by an intense
band at 1641 cm−1 and aweak one at 1622 cm−1 corresponding
to 𝛼 helix and pleated sheet structures, respectively. In con-
trast, histone modified with a 2mM ofmethylglyoxal showed
distinct variations in both peak position and intensity, sug-
gestive of changes in the histone structure uponmodification.
The bands at 1641 and 1622 cm−1 were shifted to 1643 and
1605 cm−1 inmethylglyoxal-modified histone.Theprominent
and broad peak bands in the range of 1605–1610 cm−1 indicate
a higher content of pleated structure in the modified histones
whereas the appearance of a strong band in the range of
1670–1675 cm−1 in themodified histones corresponded to the
presence of random form. A similar change in both peak
position and intensity of histone modified with RCS appears
in amide II bands in the region between 1500 and 1600 cm−1.
The diagnostic amide I IR bands corresponding to native and
modified histones are compiled in Table 2.
Table 2: Prominent FTIR amide I bands in secondary structure of
histone modified with methylglyoxal (MG).
Random coil 𝛼Helix(in cm−1) 𝛽 Sheet
Histonen — 1641 1622
MG-modified histonea 1674 1643 1605
n: native histone.
a represents 2mM concentration of the histone modifiers.
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Figure 6: Direct binding ELISA of 1 : 100 diluted type 1 diabetes
mellitus serum (type 1 DM) and normal human serum (NHS)
samples to native histone (black square) and histone modified with
1mM (orange square) and 2mM (blue square) methylglyoxal.
We have determined role of the modified histone in type
1 diabetes. This study comprised 22 serum samples from
the diseased patients while 11 samples were from healthy
controls. Serum antibodies from diabetes patients showed
appreciable binding to methylglyoxal-modified histone as
compared to the native form at 1 : 100 serum dilution (𝑃 <
0.001) in direct binding ELISA (Figure 6). Binding increased
with rise in concentration of the modifier as revealed by
absorbance studies based on ELISA.The average absorbances
(±SD) with the sera of type 1 diabetes patients binding
to native histone and histone modified with 1 and 2mM
methylglyoxal were 0.15 ± 0.03, 0.56 ± 0.07, and 0.67 ±
0.08, respectively. No appreciable binding was observed in
normal subjects. We have found antibodies to AGE modified
IgG, a lysine-rich protein, in type 1 diabetes patients [13].
Another study has shown promising result towards detection
of both lysine-derived and arginine-derived AGEs by the
induced antibodies against AGE-modified BSA [14]. There
is involvement of nonenzymatic glycosylation of proteins,
specifically on lysine residues, in age-related diseases [15, 16].
Recent studies have implicated lysine in inhibition of the
glycation process both in vitro and in vivo [17, 18].
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4. Conclusions
Theresults reported here demonstrate that spectral analysis of
methylglyoxal-modified histone provides a useful insight into
the structural perturbation of lysine and arginine residues in
histone and determines formation of AGE adducts in histone
during the 24 h incubation of histone with methylglyoxal.
Methylglyoxal-mediated histone glycation is also recognized
by serum antibodies of type 1 diabetes patients. It has been
revealed from our study that the RCS-modified histones
might be a potential target for circulating autoantibodies in
patients with type 1 diabetes mellitus and this target can be
used as a predictive biomarker for controlling the disease
complications.
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